Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSVpreF Vaccine in Pregnant Women
NCT04032093Phase 2Completed
- Sponsor
- Pfizer
- Start
- Aug 2019
- Primary completion
- Sep 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 5
01
Overview
A Phase 2 trial of RSVpreF vaccine in respiratory syncytial virus infection (RSV), sponsored by Pfizer. Started Aug 2019; status: completed.
02
Drugs
RSVpreF vaccine
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT04032093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04032093.